Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed the equity acquisition intention agreement to acquire 70% stake in Jilin Lichuang Medical Co., Ltd. and 30% stake in Haikou Boda Medical Investment Management Co., Ltd. from Shen Mingxiang and Sun Meijiao for approximately CNY 190 million on February 5, 2021. Suzhou MedicalSystem Technology Co., Ltd. will acquire 70% stake in Jilin Lichuang Medical Co., Ltd from Shen Mingxiang for CNY 112 million and 30% stake in Haikou Boda Medical Investment Management Co., Ltd. from Shen Mingxiang and Sun Meijiao for CNY 73.2 million. As of the signing date of this intentional agreement, given that the audit and evaluation of the subject matter of this transaction has not been completed, the price of this transaction is still uncertain. The specific consideration payment amount, payment method and payment period for this equity acquisition will be separately agreed upon by the two parties in a formal agreement based on the audit and evaluation results. In 2020 Jilin Lichuang Medical Co., Ltd. has Total Assets of CNY 107.4 million, net assets of CNY 55.6 million, revenue of CNY 26.7 million and net profit of CNY 3.6 million. In 2020 Haikou Boda Medical Investment has Total Assets of CNY 140.6 million, net assets of CNY 43.5 million, revenue of CNY 10.4 million and net loss of CNY 3.4 million. Transaction is subject to Suzhou MedicalSystem Technology Co., Ltd. shareholders approval. Suzhou MedicalSystem Technology Co., Ltd. held the 17th meeting of the third board of directors on February 4, 2021 to review and pass the resolution.